NEW YORK, April 17, 2015 /PRNewswire/ -- Tripp Levy PLLC, a leading national securities law firm, announces that it is investigating potential securities claims on behalf of investors of Athersys, Inc. (NASDAQ: "ATHX") ("Athersys" or the "Company") resulting from allegations that Athersys may have issued materially misleading business information to the investing public.
On April 17, 2015, Athersys announced that its in-development stem cell treatment failed to beat placebo in a Phase II trial on stroke patients. The Company's treatment, called MultiStem, is meant to reverse the neurological damage caused by strokes. Looking at 90-day interim results, MultiStem failed to chart any significant difference compared to placebo on the primary endpoint, and it failed secondary goals of improvement on two other measures of stroke rehabilitation. As a result of this announcement, the Company's stock has fallen approximately 40% during intraday trading on April 17, 2015.
If you purchased shares of Athersys and have suffered a loss from your investment in Athersys common stock and would like to learn more about this investigation, including your ability to potentially recover your losses, please contact us either by email at [email protected] or by telephone at (800) 511-7037 or visit our website at www.tripplevy.com/participate-in-an-action.
Tripp Levy PLLC is a leading national securities and shareholder rights law firm representing both individual and institutional shareholders and, along with its affiliate, have recovered billions of dollars for shareholders. Tripp Levy PLLC is affiliated with Milberg LLP. The National Law Journal has named Milberg one of the "50 Elite Trial Lawyer Firms" and one of the "50 Leading Plaintiff Firms in America."
Attorney advertising. Prior results do not indicate a similar outcome
SOURCE Tripp Levy PLLC